HomeComparePAQCW vs PFE

PAQCW vs PFE: Dividend Comparison 2026

PAQCW yields 551.42% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PAQCW wins by $131968.97M in total portfolio value
10 years
PAQCW
PAQCW
● Live price
551.42%
Share price
$0.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$131969.02M
Annual income
$97,268,998,511.44
Full PAQCW calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PAQCW vs PFE

📍 PAQCW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPAQCWPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PAQCW + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PAQCW pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAQCW
Annual income on $10K today (after 15% tax)
$46,870.69/yr
After 10yr DRIP, annual income (after tax)
$82,678,648,734.72/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PAQCW beats the other by $82,678,626,414.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAQCW + PFE for your $10,000?

PAQCW: 50%PFE: 50%
100% PFE50/50100% PAQCW
Portfolio after 10yr
$65984.54M
Annual income
$48,634,512,385.08/yr
Blended yield
73.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PAQCW
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAQCW buys
0
PFE buys
0
No recent congressional trades found for PAQCW or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPAQCWPFE
Forward yield551.42%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$131969.02M$49.6K
Annual income after 10y$97,268,998,511.44$26,258.71
Total dividends collected$129019.72M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PAQCW vs PFE ($10,000, DRIP)

YearPAQCW PortfolioPAQCW Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$65,842$55,141.99$9,153$693.39+$56.7KPAQCW
2$409,765$339,313.87$8,593$849.25+$401.2KPAQCW
3$2,412,005$1,973,556.37$8,336$1,066.78+$2.40MPAQCW
4$13,437,831$10,856,985.50$8,437$1,384.80+$13.43MPAQCW
5$70,908,154$56,529,675.10$9,013$1,875.40+$70.90MPAQCW
6$354,650,515$278,778,790.51$10,306$2,680.72+$354.64MPAQCW
7$1,682,583,925$1,303,107,873.62$12,820$4,101.38+$1682.57MPAQCW
8$7,578,300,861$5,777,936,061.91$17,673$6,826.70+$7578.28MPAQCW
9$32,429,929,418$24,321,147,496.29$27,543$12,591.86+$32429.90MPAQCW
10$131,969,022,989$97,268,998,511.44$49,560$26,258.71+$131968.97MPAQCW

PAQCW vs PFE: Complete Analysis 2026

PAQCWStock

Provident Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded in 2020 and is based in Central, Hong Kong.

Full PAQCW Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PAQCW vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAQCW vs SCHDPAQCW vs JEPIPAQCW vs OPAQCW vs KOPAQCW vs MAINPAQCW vs JNJPAQCW vs MRKPAQCW vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.